Is cetuximab-induced rash conclusion really a remnant of the skin erythema dose?
Department of Radiation Oncology, Ludwig-Maximilians-University Munich, Munich, Germany; Department of Radiation Oncology, University Hospital of Saarland, Homburg, Germany. Electronic address: feras.oskan@uniklinikum-saarland.de.
Feras
F
Oskan
Claus
C
Belka
Farkhad
F
Manapov
D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000068818:Cetuximab; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D004890:Erythema / Q000139:chemically induced* / Q000473:pathology; D005076:Exanthema / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D016019:Survival Analysis
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C512478:EGFR protein, human; D066246:ErbB Receptors; D000068818:Cetuximab